Breaking News Instant updates and real-time market news.

RIOFF

Rio2 Limited

/

+

 10:49
07/06/22
 07/06
10:49
 07/06/22
10:49

Rio2 Limited price target lowered to C$0.15 from C$0.40 at Raymond James

Raymond James analyst Craig Stanley lowered the firm's price target on Rio2 Limited to C$0.15 from C$0.40 and keeps a Market Perform rating on the shares.

OTHER BREAKING NEWS FROM THE FLY

Hot Stocks
Unity Biotechnology announces anticipated milestones » 07:17
08/12/22
08/12
07:17
08/12/22
07:17
UBX

Unity Biotechnology

/

+

UBX1325 24-week safety…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
UBX Unity Biotechnology
/

+

07:17 Today
Unity Biotechnology expects cash to fund operations through 1Q23
05/26/22
Unity Biotechnology appoints Michael Samar to board of directors
05/10/22
Unity Biotechnology announces upcoming milestones
05/05/22
Unity Biotechnology presents on UBX1325 at ARVO 2022
UBX Unity Biotechnology
/

+

05/17/22 Citi
Unity Biotechnology price target lowered to $5 from $6 at Citi
01/04/22 Roth Capital
Unity Biotechnology upgraded to Buy at Roth Capital on 2022 clinical plans
01/04/22 Roth Capital
Unity Biotechnology upgraded to Buy from Neutral at Roth Capital
12/15/21 Wedbush
Wedbush bullish on Unity Biotechnology, initiates with an Outperform
UBX Unity Biotechnology
/

+

07:16 Today
Unity Biotechnology reports Q2 EPS (19c) vs. (32c) last year
05/10/22
Unity Biotechnology reports Q1 EPS (28c), consensus (26c)
03/15/22
Unity Biotechnology reports Q4 EPS (18), consensus (38c)
Hot Stocks
PLx Pharma announces survey data on VAZALORE 81 mg » 07:17
08/12/22
08/12
07:17
08/12/22
07:17
PLXP

PLx Pharma

$2.59 /

+0.015 (+0.58%)

PLx Pharma, with its lead…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PLXP PLx Pharma
$2.59 /

+0.015 (+0.58%)

05/20/22
PLx Pharma showcases VAZALORE at SCAI annual meeting
PLXP PLx Pharma
$2.59 /

+0.015 (+0.58%)

03/15/22 BWS Financial
BWS drops coverage of PLx Pharma, says off Amazon again
12/07/21 Raymond James
Raymond James upgrades PLx Pharma on 'compelling entry point'
12/07/21 Raymond James
PLx Pharma upgraded to Outperform from Market Perform at Raymond James
11/12/21 JMP Securities
PLx Pharma reported strong quarter for Vazalore, says JMP Securities
PLXP PLx Pharma
$2.59 /

+0.015 (+0.58%)

06:55 Today
PLx Pharma reports Q2 EPS (52c), consensus (56c)
05/13/22
PLx Pharma reports Q1 non-GAAP EPS (66c), consensus (72c)
03/11/22
PLx Pharma reports Q4 adjusted EPS (73c), consensus (71c)
08:30 Today
PLx Pharma - PLXP
Hot Stocks
Unity Biotechnology expects cash to fund operations through 1Q23 » 07:17
08/12/22
08/12
07:17
08/12/22
07:17
UBX

Unity Biotechnology

/

+

Cash, cash equivalents…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
UBX Unity Biotechnology
/

+

05/26/22
Unity Biotechnology appoints Michael Samar to board of directors
05/10/22
Unity Biotechnology announces upcoming milestones
05/05/22
Unity Biotechnology presents on UBX1325 at ARVO 2022
04/28/22
Allogene Therapeutics appoints Lundeen as Chief People Officer
UBX Unity Biotechnology
/

+

05/17/22 Citi
Unity Biotechnology price target lowered to $5 from $6 at Citi
01/04/22 Roth Capital
Unity Biotechnology upgraded to Buy at Roth Capital on 2022 clinical plans
01/04/22 Roth Capital
Unity Biotechnology upgraded to Buy from Neutral at Roth Capital
12/15/21 Wedbush
Wedbush bullish on Unity Biotechnology, initiates with an Outperform
UBX Unity Biotechnology
/

+

07:16 Today
Unity Biotechnology reports Q2 EPS (19c) vs. (32c) last year
05/10/22
Unity Biotechnology reports Q1 EPS (28c), consensus (26c)
03/15/22
Unity Biotechnology reports Q4 EPS (18), consensus (38c)
Recommendations
Illumina price target lowered to $300 from $480 at Stifel » 07:16
08/12/22
08/12
07:16
08/12/22
07:16
ILMN

Illumina

$227.64 /

+0.44 (+0.19%)

Stifel analyst Daniel…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ILMN Illumina
$227.64 /

+0.44 (+0.19%)

08/11/22
Illumina cuts FY22 core Illumina revenue growth view to 3.5%-4.5%
08/11/22
Illumina drops 22% to $177 after Q2 results miss estimates, FY22 guidance cut
06/09/22
Illumina drops 6% to $210.00 after departure of CFO
06/09/22
Illumina CFO Sam Samad to depart, Joydeep Goswami named interim CFO
ILMN Illumina
$227.64 /

+0.44 (+0.19%)

06:59 Today Citi
Illumina price target lowered to $200 from $220 at Citi
06:36 Today Baird
Illumina price target lowered to $215 from $306 at Baird
08/11/22 Piper Sandler
Illumina miss 'surprising' given backlog, says Piper Sandler
07/14/22 Canaccord
Illumina merger challenge not reflection of merits, says Canaccord
ILMN Illumina
$227.64 /

+0.44 (+0.19%)

08/11/22
Illumina cuts FY22 adjusted EPS view to $2.75-$2.90 from $4.00-$4.20
08/11/22
Illumina reports Q2 adjusted EPS 57c, consensus 65c
08/11/22
Notable companies reporting after market close
05/05/22
Illumina sees FY22 adjusted EPS $4.00-$4.20, consensus $4.15
ILMN Illumina
$227.64 /

+0.44 (+0.19%)

07/27/22
Illumina's Grail deal likely to be blocked by EU regulators, Reuters reports
07/13/22
Illumina lost bid to block EU watchdog review of Grail deal, Bloomberg reports
ILMN Illumina
$227.64 /

+0.44 (+0.19%)

08/11/22
Fly Intel: After-Hours Movers
07/13/22
What You Missed On Wall Street On Wednesday
07/13/22
What You Missed On Wall Street This Morning
06/10/22
What You Missed On Wall Street On Friday
09/10/22
ESMO Congress 2022
ILMN Illumina
$227.64 /

+0.44 (+0.19%)

08/11/22
Illumina options imply 6.5% move in share price post-earnings
06/13/22
Illumina put buyer realizes 25% same-day gains
05/18/22
Early notable gainers among liquid option names on May 18th
Earnings
Unity Biotechnology reports Q2 EPS (19c) vs. (32c) last year » 07:16
08/12/22
08/12
07:16
08/12/22
07:16
UBX

Unity Biotechnology

/

+

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
UBX Unity Biotechnology
/

+

05/26/22
Unity Biotechnology appoints Michael Samar to board of directors
05/10/22
Unity Biotechnology announces upcoming milestones
05/05/22
Unity Biotechnology presents on UBX1325 at ARVO 2022
04/28/22
Allogene Therapeutics appoints Lundeen as Chief People Officer
UBX Unity Biotechnology
/

+

05/17/22 Citi
Unity Biotechnology price target lowered to $5 from $6 at Citi
01/04/22 Roth Capital
Unity Biotechnology upgraded to Buy at Roth Capital on 2022 clinical plans
01/04/22 Roth Capital
Unity Biotechnology upgraded to Buy from Neutral at Roth Capital
12/15/21 Wedbush
Wedbush bullish on Unity Biotechnology, initiates with an Outperform
UBX Unity Biotechnology
/

+

05/10/22
Unity Biotechnology reports Q1 EPS (28c), consensus (26c)
03/15/22
Unity Biotechnology reports Q4 EPS (18), consensus (38c)
Recommendations
CS Disco price target lowered to $30 from $40 at Stifel » 07:15
08/12/22
08/12
07:15
08/12/22
07:15
LAW

CS Disco

$28.96 /

+0.39 (+1.37%)

Stifel analyst J. Parker…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LAW CS Disco
$28.96 /

+0.39 (+1.37%)

06/06/22
DISCO appoints Tom Furr as CMO
06/01/22
CS Disco falls -10.8%
04/28/22
DISCO appoints Jignasha Amin Grooms as CHRO
LAW CS Disco
$28.96 /

+0.39 (+1.37%)

06:15 Today BofA
CS Disco downgraded to Neutral from Buy at BofA
06:05 Today Canaccord
CS Disco downgraded to Hold from Buy at Canaccord
05:40 Today Cowen
Cowen cuts CS Disco to Market Perform as momentum hits 'big snag'
05:35 Today Cowen
CS Disco downgraded to Market Perform from Outperform at Cowen
LAW CS Disco
$28.96 /

+0.39 (+1.37%)

08/11/22
CS Disco cuts FY22 revenue view to $132M-$136M from $149M-$153M
08/11/22
CS Disco sees Q3 revenue $32M-$34M, consensus $38.29M
08/11/22
CS Disco reports Q2 adjusted (23c), consensus (27c)
05/12/22
CS Disco sees Q2 revenue $32M-$34M, consensus $34.02M
  • 15
    Sep
LAW CS Disco
$28.96 /

+0.39 (+1.37%)

08/11/22
Fly Intel: After-Hours Movers
05/12/22
Fly Intel: After-Hours Movers
Earnings
Real Good Food raises FY22 revenue $155M-$160M from $150M-$160M » 07:15
08/12/22
08/12
07:15
08/12/22
07:15
RGF

Real Good Food

$6.93 /

-0.11 (-1.56%)

FY22 revenue consensus…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
RGF Real Good Food
$6.93 /

-0.11 (-1.56%)

08/09/22
Real Good Food Company Inc trading resumes
08/09/22
Real Good Food Company Inc trading halted, volatility trading pause
07/06/22
Real Good Food launches Real Good Foods Perks Program
06/07/22
Real Good Food announces launch of chicken enchiladas in Sam's Club
RGF Real Good Food
$6.93 /

-0.11 (-1.56%)

03/08/22 Roth Capital
Real Good Food initiated with a Buy at Roth Capital
11/30/21
Fly Intel: Top five analyst initiations
11/30/21 Jefferies
Jefferies starts Real Good Food at Buy, sees 75% upside in 12 months
11/30/21 Truist
Real Good Food initiated with a Buy at Truist
RGF Real Good Food
$6.93 /

-0.11 (-1.56%)

07:14 Today
Real Good Food reports Q2 revenue $30.809M, consensus $32.12M
05/13/22
Real Good Food sees FY22 revenue $150M-$160M, consensus $143.65M
05/13/22
Real Good Food reports Q1 revenue $37.6M, consensus $32.47M
03/11/22
Real Good Food sees 2022 revenue $140M-$150M, consensus $120.57M
  • 05
    Nov
08:30 Today
Real Good Food - RGF
General news
Market Update: » 07:15
08/12/22
08/12
07:15
08/12/22
07:15
$ECON

Economic Data

/

+

Market Update: Stock…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

06/22/22
President Biden calls on Congress to suspend federal gas tax
05/19/22
Could crypto crash be good for U.S. economy? Probably.
05/12/22
Miller calls out Taylor Morrison, GM as names that may work in this environment
04/21/22
Powell says 50 basis point hike on table for May meeting
$ECON Economic Data
/

+

$ECON Economic Data
/

+

06/14/22
Ackman says 100 point hike tomorrow 'would be better' than 75
$ECON Economic Data
/

+

07/26/22
Ackman says biggest risk to economy is inflation, not higher rates
06/17/22
White House, Congress in talks over bill to fight inflation, Bloomberg says
06/13/22
Fed more likely to consider 0.75 point hike given recent data, WSJ says
05/10/22
Tepper says covered Nasdaq short, CNBC reports
$ECON Economic Data
/

+

07/27/22
What You Missed On Wall Street On Wednesday
07/21/22
What You Missed On Wall Street On Thursday
07/21/22
What You Missed On Wall Street This Morning
07/06/22
What You Missed On Wall Street On Wednesday
Earnings
Venus Concept sees 2022 revenue $110M-$113M, consensus $126.82M » 07:14
08/12/22
08/12
07:14
08/12/22
07:14
VERO

Venus Concept

/

+

The Company now expects…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VERO Venus Concept
/

+

04/25/22
Venus Concept announces first patient treatment in study of Aime
03/31/22
Venus Concept submits FDA 510(k) for Aime robotic technology
VERO Venus Concept
/

+

06/24/22 BTIG
Venus Concept price target lowered to $5.50 from $7.00 at BTIG
11/12/21 Stifel
Venus Concept price target trimmed to $2 at Stifel after Q3 miss
VERO Venus Concept
/

+

07:14 Today
Venus Concept reports Q2 EPS (16c), consensus (7c)
03/28/22
Venus Concept sees 2022 revenue $126M-$130M, consensus $125.9M
03/28/22
Venus Concept reports Q4 EPS (8c), consensus (10c)
09/29/22
7th Annual Healthcare Conference
08:00 Today
Venus Concept - VERO
Earnings
Venus Concept reports Q2 EPS (16c), consensus (7c) » 07:14
08/12/22
08/12
07:14
08/12/22
07:14
VERO

Venus Concept

/

+

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VERO Venus Concept
/

+

04/25/22
Venus Concept announces first patient treatment in study of Aime
03/31/22
Venus Concept submits FDA 510(k) for Aime robotic technology
VERO Venus Concept
/

+

06/24/22 BTIG
Venus Concept price target lowered to $5.50 from $7.00 at BTIG
11/12/21 Stifel
Venus Concept price target trimmed to $2 at Stifel after Q3 miss
VERO Venus Concept
/

+

03/28/22
Venus Concept sees 2022 revenue $126M-$130M, consensus $125.9M
03/28/22
Venus Concept reports Q4 EPS (8c), consensus (10c)
09/29/22
7th Annual Healthcare Conference
08:00 Today
Venus Concept - VERO
Downgrade
Cellebrite downgraded to Market Perform at William Blair after guidance cut » 07:14
08/12/22
08/12
07:14
08/12/22
07:14
CLBT

Cellebrite

$5.28 /

-0.4 (-7.04%)

William Blair analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CLBT Cellebrite
$5.28 /

-0.4 (-7.04%)

07/05/22
Cellebrite and Chainalysis launch partnership
06/30/22
Cellebrite announces availability of Cellebrite Physcial Analyzer Ultra Series
05/05/22
Cellebrite announces upcoming release of Cellebrite Premium
04/06/22
Cellebrite announces national police force of EMEA expanded partnership
CLBT Cellebrite
$5.28 /

-0.4 (-7.04%)

06:06 Today William Blair
Cellebrite downgraded to Market Perform from Outperform at William Blair
05/16/22 Cowen
Cellebrite price target lowered to $13 from $17 at Cowen
05/13/22 Deutsche Bank
Cellebrite price target lowered to $10 from $11 at Deutsche Bank
02/24/22 JPMorgan
Cellebrite initiated with an Overweight at JPMorgan
CLBT Cellebrite
$5.28 /

-0.4 (-7.04%)

08/11/22
Cellebrite reports Q2 adjusted EPS 0c, consensus 3c
08/11/22
Cellebrite lowers FY22 revenue to $270M-$285M from $285M-$300M
05/12/22
Cellebrite sees FY22 revenue $285M-$300M, consensus $292.06M
05/12/22
Cellebrite reports Q1 adjusted EPS 1c, consensus 2c
CLBT Cellebrite
$5.28 /

-0.4 (-7.04%)

02/24/22
What You Missed On Wall Street On Thursday
02/24/22
What You Missed On Wall Street This Morning
02/24/22
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
Earnings
Real Good Food reports Q2 revenue $30.809M, consensus $32.12M » 07:14
08/12/22
08/12
07:14
08/12/22
07:14
RGF

Real Good Food

$6.93 /

-0.11 (-1.56%)

"I am pleased with…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RGF Real Good Food
$6.93 /

-0.11 (-1.56%)

08/09/22
Real Good Food Company Inc trading resumes
08/09/22
Real Good Food Company Inc trading halted, volatility trading pause
07/06/22
Real Good Food launches Real Good Foods Perks Program
06/07/22
Real Good Food announces launch of chicken enchiladas in Sam's Club
RGF Real Good Food
$6.93 /

-0.11 (-1.56%)

03/08/22 Roth Capital
Real Good Food initiated with a Buy at Roth Capital
11/30/21
Fly Intel: Top five analyst initiations
11/30/21 Jefferies
Jefferies starts Real Good Food at Buy, sees 75% upside in 12 months
11/30/21 Truist
Real Good Food initiated with a Buy at Truist
RGF Real Good Food
$6.93 /

-0.11 (-1.56%)

05/13/22
Real Good Food sees FY22 revenue $150M-$160M, consensus $143.65M
05/13/22
Real Good Food reports Q1 revenue $37.6M, consensus $32.47M
03/11/22
Real Good Food sees 2022 revenue $140M-$150M, consensus $120.57M
03/11/22
Real Good Food sees Q1 revenue $33M-$35M, consensus $27.33M
  • 05
    Nov
08:30 Today
Real Good Food - RGF
Syndicate
Vigil Neuroscience announces $75M private placement finanicng » 07:13
08/12/22
08/12
07:13
08/12/22
07:13
VIGL

Vigil Neuroscience

$7.29 /

+0.13 (+1.82%)

Vigil Neuroscience…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VIGL Vigil Neuroscience
$7.29 /

+0.13 (+1.82%)

08/01/22
Vigil Neuroscience presents preclinical data on VGL101
07/28/22
Vigil Neuroscience appoints Suzanne Bruhn to board of directors
07/27/22
Vigil Neuroscience granted orphan status for leukoencephalopathy treatment
06/07/22
Vigil gets HREC approval to begin study of VGL101 in healthy volunteers
VIGL Vigil Neuroscience
$7.29 /

+0.13 (+1.82%)

02/01/22 Morgan Stanley
Morgan Stanley starts Vigil at Equal Weight ahead of 2023 derisking catalysts
02/01/22 Stifel
Stifel starts Vigil Neuroscience at Buy with $24 price target
02/01/22 Guggenheim
Vigil Neuroscience initiated with a Buy at Guggenheim
02/01/22 Stifel
Vigil Neuroscience initiated with a Buy at Stifel
VIGL Vigil Neuroscience
$7.29 /

+0.13 (+1.82%)

08/08/22
Vigil Neuroscience reports Q2 EPS (60c) vs ($7.48) last year
05/12/22
Vigil Neuroscience reports Q1 EPS (58c) vs. ($5.46) last year
03/25/22
Vigil Neuroscience reports Q4 EPS ($8.28) vs. ($2.86) a year ago
  • 07
    Jan
VIGL Vigil Neuroscience
$7.29 /

+0.13 (+1.82%)

03/26/22
Opening Day: AN2 Therapeutics rises in public debut after upsized IPO
08/15/22
2022 Biotech Summer Summit
Recommendations
Brilliant Earth price target raised to $10 from $8 at KeyBanc » 07:13
08/12/22
08/12
07:13
08/12/22
07:13
BRLT

Brilliant Earth

$6.44 /

-0.17 (-2.57%)

KeyBanc analyst Noah…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BRLT Brilliant Earth
$6.44 /

-0.17 (-2.57%)

07/12/22
Brilliant Earth launches Reflections Collection
07/05/22
Brilliant Earth announces opening of showroom at Pinecrest in Cleveland
06/07/22
Brilliant Earth launches men's fine jewelry collection
06/02/22
Brilliant Earth opens 19th showroom, first location in Minnesota
BRLT Brilliant Earth
$6.44 /

-0.17 (-2.57%)

07/22/22 Piper Sandler
Brilliant Earth downgraded to Neutral from Overweight at Piper Sandler
07/21/22 KeyBanc
KeyBanc transitions coverage of Global Brands & E-Commerce with cautious view
07/20/22 KeyBanc
Brilliant Earth initiated with an Overweight at KeyBanc
06/29/22 Raymond James
Brilliant Earth initiated with an Outperform at Raymond James
BRLT Brilliant Earth
$6.44 /

-0.17 (-2.57%)

08/11/22
Brilliant Earth backs FY22 revenue view $450M-$470M, consensus $467.19M
08/11/22
Brilliant Earth reports Q2 adjusted EPS 6c, consensus 4c
05/12/22
Brilliant Earth lowers FY22 revenue view $450M-$470M from $485M-$500M
05/12/22
Brilliant Earth sees Q2 revenue $103M-$109M, consensus $115.74M
  • 23
    Sep
BRLT Brilliant Earth
$6.44 /

-0.17 (-2.57%)

07/21/22
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
Earnings
Aslan Pharmaceuticals reports Q2 EPS (4c) vs (2c) last year » 07:12
08/12/22
08/12
07:12
08/12/22
07:12
ASLN

Aslan Pharmaceuticals

/

+

Cash, cash equivalents…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ASLN Aslan Pharmaceuticals
/

+

06/07/22
Aslan in collaboration to probe IL-13Ra1 subunit role in AD
06/06/22
Aslan Pharmaceuticals to host third webinar in KOL series
05/20/22
Aslan Pharmaceuticals presents poster on eblasakimab at 2022 SID meeting
05/10/22
Aslan Pharmaceuticals reports acceptance of abstract on Eblasakimab
ASLN Aslan Pharmaceuticals
/

+

05/23/22 Piper Sandler
Aslan Pharmaceuticals price target lowered to $3 from $8 at Piper Sandler
09/27/21 Piper Sandler
Piper buyers on Aslan weakness, thinks ASLAN-004 can be competitive
ASLN Aslan Pharmaceuticals
/

+

04/27/22
Aslan Pharmaceuticals reports Q1 EPS (19c) vs. (13c) last year
03/25/22
Aslan Pharmaceuticals reports Q4 EPS (15c), consensus (14c)
Earnings
Gencor Industries reports Q3 EPS (7c) vs. 16c last year » 07:12
08/12/22
08/12
07:12
08/12/22
07:12
GENC

Gencor Industries

$9.57 /

-0.08 (-0.83%)

Reports Q3 revenue $29.6M…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GENC Gencor Industries
$9.57 /

-0.08 (-0.83%)

07/19/22
Gencor Industries transfers common stock listing to NYSE American
GENC Gencor Industries
$9.57 /

-0.08 (-0.83%)

05/13/22
Gencor Industries reports Q2 EPS 3c vs 16c last year
Recommendations
Chicken Soup for the Soul price target raised to $52 from $40 at DA Davidson » 07:10
08/12/22
08/12
07:10
08/12/22
07:10
CSSE

Chicken Soup for the Soul

/

+

, RDBX

Redbox

$1.71 /

+ (+0.00%)

, ROKU

Roku

$80.65 /

-0.33 (-0.41%)

DA Davidson analyst Tom…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CSSE Chicken Soup for the Soul
/

+

08/11/22
Chicken Soup for the Soul reports Q2 adjusted EBITDA $5.6M vs. $3.2M y/y
08/10/22
Nasdaq says Redbox trading to be halted following after-hours session on Aug. 10
08/09/22
Redbox's stockholders approve merger proposal with Chicken Soup for the Soul
07/14/22
Crackle, Popcornflix FAST channels launch on FuboTV
RDBX Redbox
$1.71 /

+ (+0.00%)

08/10/22
Nasdaq says Redbox trading to be halted following after-hours session on Aug. 10
08/09/22
Redbox's stockholders approve merger proposal with Chicken Soup for the Soul
06/14/22
Redbox down 22.5% in pre-market trading, remains most active on Stocktwits
06/13/22
Redbox up another 19% amid increase in StockTwits message volume
ROKU Roku
$80.65 /

-0.33 (-0.41%)

08/03/22
Paramount+ to launch as a Premium Subscription within Roku Channel
07/28/22
Roku drops 25% to $63.40 after Q2 results, Q3 guidance miss estimates
07/26/22
Cathie Wood's ARK Investment bought 585K shares of Roku today
06/23/22
Crackle launches updated app on Roku devices
CSSE Chicken Soup for the Soul
/

+

07/12/22 B. Riley
Chicken Soup sees positive free cash flow by year-end, says B. Riley
06/14/22 DA Davidson
DA Davidson likes Chicken Soup for the Soul amid strong box office, Redbox deal
05/27/22 B. Riley
Redbox downgraded to Sell from Neutral at B. Riley
05/17/22 Guggenheim
Chicken Soup for the Soul resumed with a Buy at Guggenheim
RDBX Redbox
$1.71 /

+ (+0.00%)

07/12/22 B. Riley
Chicken Soup sees positive free cash flow by year-end, says B. Riley
06/14/22 DA Davidson
DA Davidson likes Chicken Soup for the Soul amid strong box office, Redbox deal
05/27/22 B. Riley
Redbox downgraded to Sell from Neutral at B. Riley
05/17/22 Guggenheim
Chicken Soup for the Soul resumed with a Buy at Guggenheim
ROKU Roku
$80.65 /

-0.33 (-0.41%)

08/10/22 MoffettNathanson
MoffettNathanson downgrades Roku to sell on 'challenged' position
08/10/22 MoffettNathanson
Roku downgraded to Underperform from Market Perform at MoffettNathanson
08/08/22 Pivotal Research
Roku downgraded to Sell from Hold at Pivotal Research
08/03/22 Citi
Roku price target lowered to $125 from $165 at Citi
CSSE Chicken Soup for the Soul
/

+

08/11/22
Chicken Soup for the Soul reports Q2 EPS ($1.39), consensus (72c)
05/11/22
Chicken Soup for the Soul reports Q1 adjusted EPS (83c), consensus (71c)
03/31/22
Chicken Soup for the Soul reports Q4 EPS ($1.38), consensus (51c)
ROKU Roku
$80.65 /

-0.33 (-0.41%)

07/28/22
Roku sees Q3 revenue roughly $700M, consensus $901.73M
07/28/22
Roku reports Q2 EPS (82c), consensus (68c)
07/28/22
Notable companies reporting after market close
04/28/22
Roku backs FY22 revenue growth view of 35% y/y, consensus $3.72B
ROKU Roku
$80.65 /

-0.33 (-0.41%)

06/14/22
Netflix talked with Roku, Comcast about ad sales, The Information reports
06/08/22
Roku staff 'buzzing' about possibility of being bought by Netflix, Insider says
05/06/22
Microsoft working on Xbox Cloud streaming device for TVs, VentureBeat says
05/03/22
Roku, Apollo team to bid for minority stake in Starz, WSJ reports
CSSE Chicken Soup for the Soul
/

+

08/11/22
Fly Intel: After-Hours Movers
05/11/22
What You Missed On Wall Street On Wednesday
05/11/22
What You Missed On Wall Street This Morning
RDBX Redbox
$1.71 /

+ (+0.00%)

08/07/22
Short Report: Bed Bath Beyond in short-squeeze spotlight
08/01/22
Short Report: Bets against Beyond Meat pared as McPlant test ends
07/16/22
Short Report: Canoo shorts going along for the ride
07/09/22
Short Report: Carvana, Bed Bath Beyond short interest continues to grow
ROKU Roku
$80.65 /

-0.33 (-0.41%)

08/10/22
What You Missed On Wall Street On Wednesday
08/10/22
What You Missed On Wall Street This Morning
08/10/22
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
08/08/22
What You Missed On Wall Street On Monday
09/08/22
Consumer/Media/Entertainment Conference
09/12/22
Chicken Soup for the Soul - CSSE
09/08/22
Roku
CSSE Chicken Soup for the Soul
/

+

08/11/22
Chicken Soup for the Soul Entertainment options imply 14.7% move in share price post-earnings
08/03/22
Largest borrow rate increases among liquid names
07/15/22
Largest borrow rate increases among liquid names
07/01/22
Largest borrow rate increases among liquid names
RDBX Redbox
$1.71 /

+ (+0.00%)

06/15/22
Unusually active option classes on open June 15th
06/10/22
Redbox Entertainment Inc call volume above normal and directionally bullish
06/08/22
Unusually active option classes on open June 8th
06/07/22
Redbox Entertainment Inc call volume above normal and directionally bullish
ROKU Roku
$80.65 /

-0.33 (-0.41%)

08/02/22
Roku call volume above normal and directionally bullish
08/01/22
Unusually active option classes on open August 1st
07/28/22
Roku options imply 10.5% move in share price post-earnings
06/08/22
Unusually active option classes on open June 8th
Downgrade
Allegiant Travel downgraded to Peer Perform from Outperform at Wolfe Research » 07:10
08/12/22
08/12
07:10
08/12/22
07:10
ALGT

Allegiant Travel

$107.03 /

-0.12 (-0.11%)

Wolfe Research analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ALGT Allegiant Travel
$107.03 /

-0.12 (-0.11%)

07/25/22
Allegiant Travel reports June traffic up 9.2%
06/22/22
Allegiant Travel becomes official airline of Detroit Pistons
06/17/22
Allegiant Travel reports preliminary May traffic up 47.3% y/y
06/17/22
Allegiant Travel reports preliminary May traffic up 19.7% vs. 2019
ALGT Allegiant Travel
$107.03 /

-0.12 (-0.11%)

07:00 Today Wolfe Research
Allegiant Travel downgraded to Peer Perform from Outperform at Wolfe Research
08/10/22 Barclays
Allegiant Travel price target lowered to $150 from $180 at Barclays
08/04/22 Deutsche Bank
Allegiant Travel price target lowered to $190 from $245 at Deutsche Bank
07/26/22 Susquehanna
Allegiant Travel negative reveal suggests price sensitivity, says Susquehanna
ALGT Allegiant Travel
$107.03 /

-0.12 (-0.11%)

08/03/22
Allegiant Travel sees Q3 revenue up 29% year over three-year, consensus $589.67M
08/03/22
Allegiant Travel reports Q2 adjusted EPS 62c, consensus 92c
07/25/22
Allegiant Travel sees Q2 EPS 62c, consensus $1.38
07/25/22
Allegiant Travel sees Q2 revenue $629M, consensus $632.4M
ALGT Allegiant Travel
$107.03 /

-0.12 (-0.11%)

07/25/22
Fly Intel: After-Hours Movers
Hot Stocks
HCW Biologics expects cash to fund operations through end of 2023 » 07:10
08/12/22
08/12
07:10
08/12/22
07:10
HCWB

HCW Biologics

$2.04 /

-0.21 (-9.33%)

On June 30, 2022, the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
HCWB HCW Biologics
$2.04 /

-0.21 (-9.33%)

08/03/22
HCW Biologics announces US issued patent for platform technology
05/13/22
HCW Biologics expects cash to fund operations until end of 2023
05/05/22
HCW Biologics to present two groups of novel immunotherapeutics
04/19/22
HCW Biologics CEO to be featured speaker at CEB-2022
HCWB HCW Biologics
$2.04 /

-0.21 (-9.33%)

03/24/22 Maxim
HCW Biologics initiated with a Buy at Maxim
03/24/22 Maxim
HCW Biologics initiated with a Buy at Maxim
HCWB HCW Biologics
$2.04 /

-0.21 (-9.33%)

07:10 Today
HCW Biologics reports Q2 EPS (66c) vs (10c) last year
05/13/22
HCW Biologics reports Q1 EPS (6c) vs (69c) last year
03/28/22
HCW Biologics reports Q4 net loss $3.2M vs $2.1M last year
Earnings
HCW Biologics reports Q2 EPS (66c) vs (10c) last year » 07:10
08/12/22
08/12
07:10
08/12/22
07:10
HCWB

HCW Biologics

$2.04 /

-0.21 (-9.33%)

Reports Q2 revenue $0 vs…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
HCWB HCW Biologics
$2.04 /

-0.21 (-9.33%)

08/03/22
HCW Biologics announces US issued patent for platform technology
05/13/22
HCW Biologics expects cash to fund operations until end of 2023
05/05/22
HCW Biologics to present two groups of novel immunotherapeutics
04/19/22
HCW Biologics CEO to be featured speaker at CEB-2022
HCWB HCW Biologics
$2.04 /

-0.21 (-9.33%)

03/24/22 Maxim
HCW Biologics initiated with a Buy at Maxim
03/24/22 Maxim
HCW Biologics initiated with a Buy at Maxim
HCWB HCW Biologics
$2.04 /

-0.21 (-9.33%)

05/13/22
HCW Biologics reports Q1 EPS (6c) vs (69c) last year
03/28/22
HCW Biologics reports Q4 net loss $3.2M vs $2.1M last year
Earnings
Silver Spike Investment reports Q1 NII 4c vs. ($425.03) last year » 07:10
08/12/22
08/12
07:10
08/12/22
07:10
SSIC

Silver Spike Investment

$8.86 /

-0.33 (-3.59%)

Net asset value per share…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SSIC Silver Spike Investment
$8.86 /

-0.33 (-3.59%)

03/01/22 Piper Sandler
Silver Spike Investment initiated with an Overweight at Piper Sandler
03/01/22 Stifel
Silver Spike Investment initiated with a Hold at Stifel
  • 04
    Feb
Earnings
Instil Bio reports Q2 adjusted EPS (40c), consensus (41c) » 07:08
08/12/22
08/12
07:08
08/12/22
07:08
TIL

Instil Bio

$6.79 /

+0.09 (+1.34%)

As of June 30, 2022, we…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TIL Instil Bio
$6.79 /

+0.09 (+1.34%)

05/27/22
Instill Bio Inc trading resumes
05/27/22
Instill Bio Inc trading halted, volatility trading pause
05/27/22
Instil Bio announces IND clearance of ITIL-306
05/18/22
Instil Bio to present novel TIL analytics at ASGCT
TIL Instil Bio
$6.79 /

+0.09 (+1.34%)

06/05/22 Morgan Stanley
Instil Bio price target lowered to $9 from $14 at Morgan Stanley
08/13/21 Baird
Baird sees likely success for Instil Bio lead candidate, starts at Outperform
08/12/21 Baird
Instil Bio initiated with an Outperform at Baird
TIL Instil Bio
$6.79 /

+0.09 (+1.34%)

05/16/22
Instil Bio reports Q1 EPS (42c), consensus (38c)
03/07/22
Instil Bio reports Q4 EPS (43c), consensus (36c)
TIL Instil Bio
$6.79 /

+0.09 (+1.34%)

03/30/22
Four new option listings and one option delisting on March 30th
Hot Stocks
Rapid Micro Biosystems adopts stockholder rights plan » 07:08
08/12/22
08/12
07:08
08/12/22
07:08
RPID

Rapid Micro Biosystems

$4.21 /

-0.03 (-0.71%)

Rapid Micro Biosystems…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

07:07 Today
Rapid Micro Biosystems announces review of strategic alternatives
07:06 Today
Rapid Micro Biosystems rejects non-binding proposal from Kennedy Lewis
07:05 Today
Rapid Micro Biosystems CCO Andy Keys departs
07:05 Today
Rapid Micro Biosystems announces restructuring plan with 20% workforce reduction
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

10/14/21 Cowen
Rapid Micro Biosystems coverage transferred at Cowen
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

07:03 Today
Rapid Micro Biosystems lowers FY22 revenue view to at least $17M
07:02 Today
Rapid Micro Biosystems reports Q2 EPS (31c) vs. ($20.01) last year
05/10/22
Rapid Micro Biosystems backs FY22 revenue view $27M-$32M, consensus $29.38M
05/10/22
Rapid Micro Biosystems reports Q1 EPS (35c), consensus (33c)
08:30 Today
Rapid Micro Biosystems - RPID
Hot Stocks
Rapid Micro Biosystems announces review of strategic alternatives » 07:07
08/12/22
08/12
07:07
08/12/22
07:07
RPID

Rapid Micro Biosystems

$4.21 /

-0.03 (-0.71%)

Rapid Micro Biosystems…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

07:06 Today
Rapid Micro Biosystems rejects non-binding proposal from Kennedy Lewis
07:05 Today
Rapid Micro Biosystems CCO Andy Keys departs
07:05 Today
Rapid Micro Biosystems announces restructuring plan with 20% workforce reduction
06/30/22
Rapid Micro confirms receipt of non-binding proposal from Kennedy Lewis
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

10/14/21 Cowen
Rapid Micro Biosystems coverage transferred at Cowen
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

07:03 Today
Rapid Micro Biosystems lowers FY22 revenue view to at least $17M
07:02 Today
Rapid Micro Biosystems reports Q2 EPS (31c) vs. ($20.01) last year
05/10/22
Rapid Micro Biosystems backs FY22 revenue view $27M-$32M, consensus $29.38M
05/10/22
Rapid Micro Biosystems reports Q1 EPS (35c), consensus (33c)
08:30 Today
Rapid Micro Biosystems - RPID
Recommendations
Marriott Vacations price target lowered to $202 from $205 at Truist » 07:07
08/12/22
08/12
07:07
08/12/22
07:07
VAC

Marriott Vacations

$146.63 /

+1.64 (+1.13%)

Truist analyst Patrick…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VAC Marriott Vacations
$146.63 /

+1.64 (+1.13%)

08/01/22
Marriott Vacations raises share repurchase authorization by $500M
06/16/22
Marriott Vacations raises 2022 contract sales guidance by $100M
06/09/22
Marriott Vacations CEO Stephen Weisz to retire, John Geller, Jr to succeed
02/23/22
Marriott Vacations sees FY22 contract sales up 13% vs. 2019
VAC Marriott Vacations
$146.63 /

+1.64 (+1.13%)

08/10/22 Barclays
Marriott Vacations price target raised to $165 from $136 at Barclays
08/10/22 Deutsche Bank
Marriott Vacations price target raised to $192 from $188 at Deutsche Bank
06/28/22 Barclays
Barclays says shift in preferences to cushion Gaming, Cruises, Timeshare names
06/28/22 Barclays
Marriott Vacations initiated with an Overweight at Barclays
VAC Marriott Vacations
$146.63 /

+1.64 (+1.13%)

08/08/22
Marriott Vacations sees FY22 adjusted EPS $9.47-$10.35, consensus $9.49
08/08/22
Marriott Vacations reports Q2 adjusted EPS $2.87, consensus $2.27
05/05/22
Marriott Vacations sees FY22 adjusted EPS $9.13-$10.09, consensus $9.22
05/05/22
Marriott Vacations reports Q1 adjusted EPS $1.70, consensus $1.53

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.